Literature DB >> 20013809

Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1.

Kevin T P Ng1, Terence K W Lee, Qiao Cheng, Jana Y H Wo, Chris K W Sun, Dong-Yong Guo, Zophia X Lim, Chung-Mau Lo, Ronnie T P Poon, Sheung-Tat Fan, Kwan Man.   

Abstract

We previously demonstrated that the overexpression of homeoprotein Six1 in hepatocellular carcinoma (HCC) patients is associated with venous infiltration, advanced pathologic tumor metastasis (pTNM) stage and poor overall survival rate (Ng et al. Br J Cancer 2006;95:1050-5). In this study, short hairpin RNA (shRNA) interference approach was used to suppress the expression of Six1 in a metastatic HCC cell line MHCC97L. Stable transfectant MHCC97L-shSix1 carrying Six1-specific shRNA plasmid was established to downregulate Six1 expression to about 40% when compared with MHCC97L-Control. In vitro functional assays demonstrated that the growth rate and proliferation ability of MHCC97L-shSix1 cells were markedly decreased. Moreover, significant decrease of cell motility and invasiveness were observed in MHCC97L-shSix1 cells. Data from in vivo xenograft tumorigenesis model demonstrated that the size of tumor in MHCC97L-shSix1 group was dramatically reduced. Experimental and spontaneous metastasis models indicated that targeting Six1 suppression noticeably reduced the pulmonary metastasis in MHCC97L-shSix1 group. To identify Six1-regulated targets, cDNA microarray was employed to compare the expression profiles of MHCC97L-Control and MHCC97L-shSix1 cells. Twenty-eight downregulated and 24 upregulated genes with known functions were identified in MHCC97L-shSix1. The functions of these target genes are involved in diverse biological activities. Our data suggest that Six1 may be involved in regulation of proliferation and invasiveness of HCC; thus targeting suppression of Six1 is a viable option for treating HCC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013809     DOI: 10.1002/ijc.25105

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Authors:  Aaron B Krueger; Seameen J Dehdashti; Noel Southall; Juan J Marugan; Marc Ferrer; Xueni Li; Heide L Ford; Wei Zheng; Rui Zhao
Journal:  J Biomol Screen       Date:  2012-07-20

2.  Inhibition of Six1 promotes apoptosis, suppresses proliferation, and migration of osteosarcoma cells.

Authors:  Liu Hua; Liu Fan; Wei Aichun; Zhou Yongjin; Chen Qingqing; Wang Xiaojian
Journal:  Tumour Biol       Date:  2013-10-11

3.  Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion.

Authors:  Zhaoming Li; Tian Tian; Xiaopeng Hu; Xudong Zhang; Lifeng Li; Feifei Nan; Yu Chang; Xinhua Wang; Zhenchang Sun; Feng Lv; Mingzhi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

4.  Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.

Authors:  Hengbo Zhou; Melanie A Blevins; Jessica Y Hsu; Deguang Kong; Matthew D Galbraith; Andrew Goodspeed; Rachel Culp-Hill; Michael U J Oliphant; Dominique Ramirez; Lingdi Zhang; Jennyvette Trinidad-Pineiro; Lesley Mathews Griner; Rebecca King; Elena Barnaeva; Xin Hu; Noel T Southall; Marc Ferrer; Daniel L Gustafson; Daniel P Regan; Angelo D'Alessandro; James C Costello; Samarjit Patnaik; Juan Marugan; Rui Zhao; Heide L Ford
Journal:  Cancer Res       Date:  2020-04-27       Impact factor: 12.701

5.  MicroRNA-23a inhibits endometrial cancer cell development by targeting SIX1.

Authors:  Hong-Lin Li; Jun-Jie Sun; Hui Ma; Shen-Jia Liu; Na Li; Su-Jie Guo; Yang Shi; Yan-Ying Xu; Zhi-Ying Qi; Yu-Quan Wang; Fang Wang; Rui-Meng Guo; Dong Liu; Feng-Xia Xue
Journal:  Oncol Lett       Date:  2019-07-31       Impact factor: 2.967

Review 6.  The SIX1-EYA transcriptional complex as a therapeutic target in cancer.

Authors:  Melanie A Blevins; Christina G Towers; Aaron N Patrick; Rui Zhao; Heide L Ford
Journal:  Expert Opin Ther Targets       Date:  2015-01-02       Impact factor: 6.902

7.  SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.

Authors:  Chu-An Wang; Paul Jedlicka; Aaron N Patrick; Douglas S Micalizzi; Kimberly C Lemmer; Erin Deitsch; Matias Casás-Selves; J Chuck Harrell; Heide L Ford
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

8.  Six1 overexpression at early stages of HPV16-mediated transformation of human keratinocytes promotes differentiation resistance and EMT.

Authors:  Hanwen Xu; Lucia Pirisi; Kim E Creek
Journal:  Virology       Date:  2014-11-17       Impact factor: 3.616

9.  Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes.

Authors:  Hanwen Xu; Yu Zhang; Diego Altomare; Maria M Peña; Fang Wan; Lucia Pirisi; Kim E Creek
Journal:  Carcinogenesis       Date:  2014-02-26       Impact factor: 4.944

10.  SIX1/EYA1 are novel liver damage biomarkers in chronic hepatitis B and other liver diseases.

Authors:  Baoyan Xu; Qiao Yang; Yingzi Tang; Zhaoxia Tan; Haiyan Fu; Jing Peng; Xiaomei Xiang; Linlin Gan; Guohong Deng; Qing Mao; Pin-Xian Xu; Yi Jiang; Jianqiang Ding
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.